Determinants of therapeutic lag in multiple sclerosis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F21%3A10432955" target="_blank" >RIV/00216208:11110/21:10432955 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/21:10432955

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=heU1MzqaeE" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=heU1MzqaeE</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1177/1352458520981300" target="_blank" >10.1177/1352458520981300</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Determinants of therapeutic lag in multiple sclerosis

Popis výsledku v původním jazyce

Background: A delayed onset of treatment effect, termed therapeutic lag, may influence the assessment of treatment response in some patient subgroups. Objectives: The objective of this study is to explore the associations of patient and disease characteristics with therapeutic lag on relapses and disability accumulation. Methods: Data from MSBase, a multinational multiple sclerosis (MS) registry, and OFSEP, the French MS registry, were used. Patients diagnosed with MS, minimum 1 year of exposure to MS treatment and 3 years of pre-treatment follow-up, were included in the analysis. Studied outcomes were incidence of relapses and disability accumulation. Therapeutic lag was calculated using an objective, validated method in subgroups stratified by patient and disease characteristics. Therapeutic lag under specific circumstances was then estimated in subgroups defined by combinations of clinical and demographic determinants. Results: High baseline disability scores, annualised relapse rate (ARR) &gt; 1 and male sex were associated with longer therapeutic lag on disability progression in sufficiently populated groups: females with expanded disability status scale (EDSS) &lt; 6 and ARR &lt; 1 had mean lag of 26.6 weeks (95% CI = 18.2-34.9), males with EDSS &lt; 6 and ARR &lt; 1 31.0 weeks (95% CI = 25.3-36.8), females with EDSS &lt; 6 and ARR &gt; 1 44.8 weeks (95% CI = 24.5-65.1), and females with EDSS &gt; 6 and ARR &lt; 1 54.3 weeks (95% CI = 47.2-61.5). Conclusions: Pre-treatment EDSS and ARR are the most important determinants of therapeutic lag.

Název v anglickém jazyce

Determinants of therapeutic lag in multiple sclerosis

Popis výsledku anglicky

Background: A delayed onset of treatment effect, termed therapeutic lag, may influence the assessment of treatment response in some patient subgroups. Objectives: The objective of this study is to explore the associations of patient and disease characteristics with therapeutic lag on relapses and disability accumulation. Methods: Data from MSBase, a multinational multiple sclerosis (MS) registry, and OFSEP, the French MS registry, were used. Patients diagnosed with MS, minimum 1 year of exposure to MS treatment and 3 years of pre-treatment follow-up, were included in the analysis. Studied outcomes were incidence of relapses and disability accumulation. Therapeutic lag was calculated using an objective, validated method in subgroups stratified by patient and disease characteristics. Therapeutic lag under specific circumstances was then estimated in subgroups defined by combinations of clinical and demographic determinants. Results: High baseline disability scores, annualised relapse rate (ARR) &gt; 1 and male sex were associated with longer therapeutic lag on disability progression in sufficiently populated groups: females with expanded disability status scale (EDSS) &lt; 6 and ARR &lt; 1 had mean lag of 26.6 weeks (95% CI = 18.2-34.9), males with EDSS &lt; 6 and ARR &lt; 1 31.0 weeks (95% CI = 25.3-36.8), females with EDSS &lt; 6 and ARR &gt; 1 44.8 weeks (95% CI = 24.5-65.1), and females with EDSS &gt; 6 and ARR &lt; 1 54.3 weeks (95% CI = 47.2-61.5). Conclusions: Pre-treatment EDSS and ARR are the most important determinants of therapeutic lag.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30103 - Neurosciences (including psychophysiology)

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Multiple Sclerosis Journal

ISSN

1352-4585

e-ISSN

—

Svazek periodika

27

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

14

Strana od-do

1838-1851

Kód UT WoS článku

000677275500001

EID výsledku v databázi Scopus

2-s2.0-85099300704